Fresenius Kabi is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. Through our recent acquisition of Fenwal, we bring over 60 years experience advancing the fields of cell collection and separation with a deep expertise in closed-system processing. We recently launched Lovo, the only cell processing system that washes and concentrates white blood cells using filtration technology, specifically to serve the needs of the cellular therapies community.
GenesisBPS is a global manufacturer and supplier of precision equipment to clinical laboratories, life science customers, blood collection and cellular therapy organizations. Our product portfolio represents quality and consistency in a world of ever-changing requirements for collection, processing, safe storage and transport. Technology continues to take us further into the realm of medical possibility and to the edge of bio-scientific advancement.
Genscript is a leading biotech company providing life sciences services and products to scientists over 100 countries worldwide. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading biotech company specializing in fundamental life sciences research, translational biomedical research, and early stage pharmaceutical development.
HemaCare is a leading blood products and services company serving the scientific community. HemaCare provides healthy and disease state human primary blood cells derived from normal and mobilized peripheral blood, bone marrow and cord blood for advanced biomedical research. HemaCare also supports cell therapy research, clinical trials and commercialization with customized apheresis collections, and provides a wide range of consulting services in SOP development, personnel training, quality and regulatory compliance. www.hemacare.com
Huacells is vigorously pursuing systems to optimize human t-cell culture. The exploding interest in autologous and engineered t-cell therapies speaks to a need for single use sterile disposable systems. As well as is pioneering automatic cell culture systems, Huacells is optimizing activation and expansion protocols; and working in close collaboration with a GMP level producer of culture media to ensure the highest possible culture cycle success rate.
InVitria, a division of Ventria Bioscience, was founded with the goal of providing the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria does this by allowing customers to eliminate animal components from their cell-based processes. Removing these components helps improve consistency, safety and efficiency. InVitria’s products are recombinant proteins that are manufactured in our manufacturing facility in Junction City, Kansas.
Key Biologics provides biological products to the cell therapy industry worldwide. Non-mobilized and G-CSF mobilized MNC collections are performed under proprietary IRB-approved protocols. Three G-CSF schedules are available: 4day/10ug per kg/single collection, 5day/10ug per kg/single collection and 5day/5ug per kg/two collections. Key operates the Spectra, Optia and Amicus devices allowing customers to compare MNC product characteristics that could influence manufacturing of autologous or allogeneic cell-based therapies.
Kite Pharma is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development. For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
MaxCyte’s flow electroporation is driving the next generation of cell-based medicines. Used in the discovery, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.